Abstract
Hydroxychloroquine and quinacrine are frequently used to treat rheumatic diseases. Ocular toxicity, although infrequent, is one of the potential side effects of antimalarial therapies. Current recommendations are unifocal in being developed by only ophthalmologists who do not treat patients for their rheumatic diseases. The data used to create the recommendations are meager and retrospective. Comanagement of patients with rheumatic disease who are exposed to antimalarial therapies requires a greater interaction between ophthalmologists and rheumatologists.
| Original language | English |
|---|---|
| Pages (from-to) | 359-367 |
| Number of pages | 9 |
| Journal | Rheumatic Disease Clinics of North America |
| Volume | 45 |
| Issue number | 3 |
| DOIs | |
| State | Published - Aug 2019 |
| Externally published | Yes |
Keywords
- Antimalarials
- Hydroxychloroquine
- Ocular toxicity
- Quinacrine
- Retinopathy